Drugs / Recombinant Meningococcal Group B Vaccine (E. Coli)
Recombinant Meningococcal Group B Vaccine (E. Coli)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06314880 | Jul 2023 → Dec 2024 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Meningococcal Group B Vaccine (E. Coli) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314880 ↗ |
| Modality | Vaccine | “recombinant Group B meningococcal vaccine (E. coli)” NCT06314880 ↗ |